FDA Committee Suggests Flexible Approach to Qualifying Data

April 5, 2017
Drugs Regulatory Affairs
The FDA should give developers of generic drugs more flexibility to use model-informed data, an advisory committee said.

To View This Article:

Login

Subscribe To Generic Line

Upcoming Events

Featured Products

Featured Stories

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More